Index. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.

Transcription

1 Note: Page numbers of article titles are in boldface type. A Abatacept for DLE, 493 for SLE, 497 Ablative therapies, localized, for cutaneous T-cell lymphoma, See also Cutaneous T-cell lymphoma, treatment of, localized ablative therapies in. Acne vulgaris, zinc for, Acneiform dermatoses, zinc for, Acreodermatitis enteropathica, 589 Actinic prurigo, thalidomide for, 579 Acute generalized exanthematous pustulosis (AGEP), topical metronidazole for, Acute zinc deficiency, 589 Adalimumab described, 560 for HS, AGEP. See Acute generalized exanthematous pustulosis (AGEP). Alefacept, for HS, 515 Alopecia, androgenetic. See Androgenetic alopecia. Alopecia areata, in children, innovative therapeutics in, Androgen(s), androgenetic alopecia and, Androgenetic alopecia androgens and, genetics and, 612 zinc for, 591 Angioma(s), in children, innovative therapeutics in, Antibiotic(s), for recurrent furunculosis, Antimalarial agents, for SCLE, 494 Aphthous stomatitis, thalidomide for, Atopic dermatitis, in children, innovative therapeutics in, B B-cell lymphoma, cutaneous, primary, rituximab for, Behçet disease thalidomide for, 578 TNF-a for, 566 Belimumab, for SLE, 497 Benign familial pemphigus, TNF-a for, Bexarotene gel, for severe hand dermatitis, 459 Biologic drugs, for HS, Dermatol Clin 28 (2010) doi: /s (10) /10/$ see front matter ª 2010 Elsevier Inc. All rights reserved. adalimumab, alefacept, 515 described, efalizumab, 515 etanercept, evidence-based grading of, 513 infliximab, 516, Botulinum toxin, for severe hand dermatitis, 459 Bullous pemphigoid rituximab for, TNF-a for, 564 C Calcineurin inhibitors, topical, See also Topical calcineurin inhibitors. Chloroquine, for DLE, 493 Cholestatic itch, Chronic cutaneous ulcers, zinc for, 593 Chronic inflammatory dermatoses, dapsone for, dosage of, 605 CLASI. See Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI). Community-acquired MRSA diagnosis of, 481 furunculosis and, molecular pathogenesis of, 480 risk factors for, treatment of, 481 Contact dermatitis, topical calcineurin inhibitors for, 537 Corticosteroid(s) for SCLE, 494 for severe hand dermatitis, Crohn disease, cutaneous, topical calcineurin inhibitors for, Cryotherapy, for cutaneous T-cell lymphoma, Cutaneous B-cell lymphoma, primary, rituximab for, Cutaneous Crohn disease, topical calcineurin inhibitors for, Cutaneous lupus erythematosus rituximab for, 551 Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI), 489 Cutaneous T-cell lymphoma, described, 501 derm.theclinics.com

2 632 Cutaneous (continued) incidence of, 501 treatment of dichotomies in positioning therapies in, localized ablative therapies in, cryotherapy, excimer laser, 504, 505 imiquimod, 504, 506, 507 photodynamic therapy, 502, 503 surgery, 504 palliation-related, generalized therapy in, 506 remission-related, generalized therapy in, 508 stem cell transplantation in, 508 Cutaneous ulcers, chronic, zinc for, 593 Cyclophosphamide plus azathioprine, for SLE, 496 D Dandruff, zinc for, 591 Dapsone adverse events with, characteristics of, 603 chemistry of, clinical use of, dermatologic reactions to, 607 described, 599 gastrointestinal/hepatic reactions to, hematologic effects of, 606 hypersensitivity syndrome with, 608 in chronic inflammatory dermatoses, dosage of, 605 innovative uses for, mechanism of action of, monitoring guidelines, nervous system effects of, 607 pharmacology of, pitfalls of, Dermatitis atopic, in children, innovative therapeutics in, contact, diaper, zinc for, hand, See Hand dermatitis. perioral, periorificial, topical metronidazole for, seborrheic topical metronidazole for, 527 zinc for, 591 zinc for, Dermatomyositis rituximab for, 551 TNF-a for, Dermatosis(es) acneiform, zinc for, chronic inflammatory, dapsone for, dosage of, 605 inflammatory, chronic, dapsone for, dosage of, 605 perioral, subcorneal pustular, TNF-a for, 563 Diaper dermatitis, zinc for, Discoid lupus erythematosus (DLE) described, 491 treatment of, See also specific agents. DLE. See Discoid lupus erythematosus (DLE). Drug eruptions, fixed, topical metronidazole for, 531 E Eczema, zinc for, 591 Efalizumab for DLE, for HS, 515 Environmental decontamination, for recurrent furunculosis, 484 Epidermal growth factor receptor inhibitor associated cutaneous toxicity, topical metronidazole for, Epidermolysis bullosa acquisita, rituximab for, 549 Epratuzumab, for SLE, 497 Erythema annular centrifigum, TNF-a for, 569 Erythema multiforme, thalidomide for, 580 Etanercept described, 560 for HS, Excimer laser, for cutaneous T-cell lymphoma, 504, 505 F Female pattern hair loss (FPHL) androgens and, causes of, clinical features of, diagnosis of, genetics and, 612 pathophysiology of, 613 treatment of, 614 spironolactone in, innovative use of, See also Spironolactone, in FPHL management, innovative use of. Fixed drug eruptions, topical metronidazole for, 531 Folliculitis decalvans, zinc for, 590 FPHL. See Female pattern hair loss (FPHL). Furunculosis, bacterial milieu in, chronic colonization in, treatment of, environmental decontamination in, 484 community acquired MRSA and, See also Community-acquired MRSA, furunculosis and.

3 633 G diagnosis of, 481 molecular pathogenesis of, bacterial milieu in, 480 recurrent prevention of, vaccines in, 486 treatment of, antibiotics in, environmental decontamination in, 484 for colonization in chronic furunculosis, phages in, 484 risk factors for, treatment of, 481 Genetic(s), in androgenetic alopecia, 612 Genodermatoses, in children, innovative therapeutics in, Graft-versus-host disease (GVHD) rituximab for, thalidomide for, TNF-a for, Granuloma annulare, TNF-a for, 561 GVHD. See Graft-versus-host disease (GVHD). H Hailey-Hailey disease, TNF-a for, Hair, conditions affecting, zinc for, 591 Hand dermatitis causes of, 454 classification of, described, 453 epidemiology of, 454 quality-of-life effects of, severe, defined, 453 diagnosis of, laboratory studies in, occupation in, patch testing in, severity assessments in, 455 prevention of, 458 risk factors for, 457 treatment of, corticosteroids in, ionizing radiation in, 459 systemic therapy in, topical agents in, Hidradenitis suppurativa (HS), described, 511 diagnosis of, 512 symptoms of, TNF-a for, 570 treatment of biologic drugs in, See also specific drugs and Biologic drugs, for HS. tradition therapies in, zinc for, 590 Histiocytosis, Langerhans cell, thalidomide for, 580 HS. See Hidradenitis suppurativa (HS). Hydroxychloroquine, for DLE, 493 Hypersensitivity syndrome, dapsone and, 608 I Imiquimod, for cutaneous T-cell lymphoma, 504, 506, 507 Immune diseases, in children, innovative therapeutics in, Immunoglobulin(s), intravenous for SLE, Infectious diseases in children, innovative therapeutics in, zinc for, 592 Inflammatory dermatoses, chronic, dapsone for, dosage of, 605 Infliximab described, for HS, 516, Intravenous immunoglobulin (IVIG) for SLE, Ionizing radiation, for severe hand dermatitis, 459 Itch. See also Pruritus. cholestatic, defined, 467 neuropathic, IVIG. See Intravenous immunoglobulin (IVIG). J Jessner lymphocytic infiltrate, thalidomide for, 581 K Kaposi sarcoma, thalidomide for, 581 L Langerhans cell histiocytosis, thalidomide for, 580 Laser(s) excimer, for cutaneous T-cell lymphoma, 504 pulsed dye, for DLE, 494 Leflunomide, Leishmaniasis, old-world cutaneous, zinc for, 592 Lenalidomide, for DLE, 493 Lichen planus, thalidomide for, Lichen sclerosus, topical calcineurin inhibitors for, 538 Local zinc deficiency, 593

4 634 Localized ablative therapies, for cutaneous T-cell lymphoma, See also specific types and Cutaneous T-cell lymphoma, treatment of, localized ablative therapies in. Lupus erythematosus, See also specific types, e.g., Systemic lupus erythematosus (SLE). classification of, cutaneous presentation of, 489 rituximab for, 551 subacute, described, 489 discoid, treatment of, See also Discoid lupus erythematosus (DLE). systemic. See Systemic lupus erythematosus (SLE). thalidomide for, Lymphoma(s) B-cell, cutaneous, primary, rituximab for, T-cell, cutaneous, See also Cutaneous T-cell lymphoma. M Melasma, zinc for, 593 Methicillin-resistant Staphylococcus aureus (MRSA), community-acquired, furunculosis and, See also Community-acquired MRSA, furunculosis and. Metronidazole, topical, for rosacea, optimal use, innovative uses of, AGEP, epidermal growth factor receptor inhibitor associated cutaneous toxicity, fixed drug eruptions, 531 periorificial dermatitis, seborrheic dermatitis, 527 smelly wounds, mechanism of action of, 525 pharmacology of, 525 Moderate systemic zinc deficiency, 587 Morphea/scleroderma, topical calcineurin inhibitors for, 538 MRSA. See Methicillin-resistant Staphylococcus aureus (MRSA). Mucous membrane pemphigoid rituximab for, 550 TNF-a for, 564 Multicentric reticulohistiocytosis, TNF-a for, Mycophenolate mofetil for SLE, 497 N Necrobiosis lipoidica diabeticorum thalidomide for, 582 TNF-a for, Necrolytic acral erythema, zinc for, Netherton syndrome, topical calcineurin inhibitors for, 538 Neuropathic itch, Neuropathy(ies), peripheral, thalidomide and, 582 O Old-world cutaneous leishmaniasis, zinc for, 592 Oral lichen planus, topical calcineurin inhibitors for, P Paraneoplastic pemphigus, rituximab for, PASI. See Psoriasis Area Severity (PASI). Patch testing, in severe hand dermatitis, PDL. See Pulsed dye laser (PDL). Pediatric dermatology, innovative therapeutics in, alopecia areata, angiomas, atopic dermatitis, genodermatoses, immune diseases, infectious diseases, psoriasis, 624 scleroderma, 627 vitiligo, Pemphigus foliaceus, rituximab for, Pemphigus vulgaris, rituximab for, Perioral dermatitis, topical calcineurin inhibitors for, 537 Periorificial dermatitis, topical metronidazole for, Peripheral neuropathy, thalidomide and, 582 Phage(s), for recurrent furunculosis, 484 Photodynamic therapy, for cutaneous T-cell lymphoma, 502, 503 Pimecrolimus additional indications for, 539 for DLE, 492 for lichen sclerosus, 538 for Netherton syndrome, 538 for oral lichen planus, 535 for psoriasis, 537 for SLE, 496 for vitiligo, 536 Pityriasis rubra pilaris, TNF-a for, Primary cutaneous B-cell lymphoma, rituximab for,

5 635 Prurigo nodularis, thalidomide for, 579 Pruritus, See also Itch. classification of, 467 defined, 467 renal, uremic, thalidomide for, 581 workup for, Psoriasis in children, innovative therapeutics in, 624 topical calcineurin inhibitors for, zinc for, 593 Psoriasis Area Severity (PASI), 489 Pulsed dye laser (PDL), for DLE, 494 Pyoderma gangrenosum thalidomide for, TNF-a for, Q Quality of life, severe hand dermatitis effects on, Quinacrine, for DLE, 493 R Radiation, ionizing, for severe hand dermatitis, 459 Recalcitrant viral warts, zinc for, 592 Renal pruritus, Reticulohistiocytosis, multicentric, TNF-a for, Rituximab, adverse effects of, incidence of, described, 547 dosing regimen for, 547 for SLE, 497 indications for, 547 off-label uses of, bullous pemphigoid, cutaneous lupus erythematosus, 551 dermatomyositis, 551 epidermolysis bullosa acquisita, 549 GVHD, mucous membrane pemphigoid, 550 paraneoplastic pemphigus, pemphigus foliaceus, pemphigus vulgaris, primary cutaneous B-cell lymphoma, 550 vasculitis, 552 Romidepsin, for cutaneous T-cell lymphoma, 506 Rosacea topical metronidazole for, optimal use, zinc for, 590 R-salbutamol, for DLE, 493 S SAPHO syndrome, TNF-a for, 568 Sarcoidosis thalidomide for, 579 TNF-a for, Sarcoma(s), Kaposi, thalidomide for, 581 Scleroderma in children, innovative therapeutics in, 627 TNF-a for, 565 Scleromyxedema, thalidomide for, 582 Seborrheic dermatitis topical metronidazole for, 527 zinc for, 591 SLE. See Systemic lupus erythematosus (SLE). Smelly wounds, topical metronidazole for, Spironolactone described, 614 in FPHL management, See also Female pattern hair loss (FPHL). mechanism of action of, 615 response to, monitoring of, Staphylococcus aureus, methicillin-resistant, community-acquired, furunculosis and, See also Community-acquired MRSA, furunculosis and. Stem cell transplantation, for cutaneous T-cell lymphoma, 508 Stomatitis, aphthous, thalidomide for, Subacute cutaneous lupus erythematosus (SCLE), described, 494 treatment of, See also specific agents. Subcorneal pustular dermatosis, TNF-a for, 563 Sunscreens, for SCLE, 494 Sweet syndrome, TNF-a for, 563 Systemic lupus erythematosus (SLE) described, TNF-a for, treatment of, See also specific agents. T Tacrolimus, indications for, 492, 495, DLE, 492 lichen sclerosus, 538 Netherton syndrome, 538 oral lichen planus, 535 psoriasis, SCLE, 495 SLE, 496 vitiligo, 536 T-cell lymphoma, cutaneous, See also Cutaneous T-cell lymphoma. Telgen effluvium, zinc for, 591 Teratogenicity, thalidomide and, 582

6 636 Thalidomide adverse effects of, contraindications, 582 described, 577 off-label uses of, actinic prurigo, 579 aphthous stomatitis, Behçet disease, 578 erythema multiforme, 580 GVHD, Jessner lymphocytic infiltrate, 581 Kaposi sarcoma, 581 Langerhans cell histiocytosis, 580 lichen planus, lupus erythematosus, necrobiosis lipoidica diabeticorum, 582 prurigo nodularis, 579 pyoderma gangrenosum, sarcoidosis, 579 scleromyxedema, 582 uremic pruritus, 581 pharmacology of, 577 Thromboembolic events, thalidomide and, TNF-a. See Tumor necrosis factor-a (TNF-a). Topical calcineurin inhibitors, See also specific agents. innovative uses of contact dermatitis, 537 cutaneous Crohn disease, cutaneous lupus erythematosus, 537 DLE, 492 lichen sclerosus, 537 morphea/scleroderma, 538 Netherton syndrome, 538 oral lichen planus, perioral dermatitis, 537 psoriasis, rosacea, 537 seborrheic dermatitis, 537 vitiligo, 536 Topical metronidazole, See also Metronidazole, topical. Toxic epidermal necrolysis thalidomide for, contraindications, 582 TNF-a for, 569 Transplantation(s), stem cell, for cutaneous T-cell lymphoma, 508 Tumor necrosis factor-a (TNF-a), described, 559 Tumor necrosis factor-a (TNF-a) inhibitors, adalimumab, 560 etanercept, 560 infliximab, off-label uses of, Behçet disease, 566 bullous pemphigoid, 564 dermatomyositis, U erythema annular centrifigum, 569 granuloma annulare, 561 GVHD, Hailey-Hailey disease, hidradenitis suppurativa, 570 mucous membrane pemphigoid, 564 multicentric reticulohistiocytosis, necrobiosis lipoidica diabeticorum, pityriasis rubra pilaris, pyoderma gangrenosum, SAPHO syndrome, 568 sarcoidosis, scleroderma, 565 SLE, subcorneal pustular dermatosis, 563 Sweet syndrome, 563 toxic epidermal necrolysis, 569 vasculitis, 563 Ulcer(s), cutaneous, chronic, zinc for, 593 Uremic pruritus, thalidomide for, 581 V Vaccine(s), in recurrent furunculosis prevention, 486 Vaculitis-related conditions, zinc for, 591 Vasculitis rituximab for, 552 TNF-a for, 563 Viral warts, recalcitrant, zinc for, 592 Vitamin D for SLE, 496 plus calcium, for SCLE, 494 Vitiligo in children, innovative therapeutics in, topical calcineurin inhibitors for, 536 W Wart(s), viral, recalcitrant, zinc for, 592 Wound(s), smelly, topical metronidazole for, Z Zinc abnormalities associated with, dermatologic diseases attributed to, described, 587 innovative uses of, acne vulgaris, acneiform dermatoses, androgenetic alopecia, 591 chronic cutaneous ulcers, 593

7 637 conditions affecting hair, 591 dandruff, 591 dermatitis, diaper dermatitis, eczema, 591 folliculitis decalvans, 590 hidradenitis suppurativa, 590 indications for, 588 infectious diseases, 592 melasma, 593 necrolytic acral erythema, old-world cutaneous leishmaniasis, 592 psoriasis, 593 recalcitrant viral warts, 592 rosacea, 590 seborrheic dermatitis, 591 study of discussion, methods, 587 results, telgen effluvium, 591 vasculitis conditions, 591